Science Raises $230M in Series C Funding to Advance Neural Engineering Platform

Science Corporation just raised $230M and managed to turn heads without yelling from a rooftop. Quiet confidence tends to do that, especially when the mission is restoring vision itself.

Founded in 2021, Science Corporation has been building something that sounds like it belongs in a Philip K. Dick novel but sits very comfortably in real operating rooms. Brain computer interfaces designed to restore human capability. Not theory. Not someday. Real devices moving through clinical pathways. Founder and CEO Max Hodak has been clear about the thesis from day one. If you want to solve problems that matter, start with the nervous system and work outward.

The headline product is PRIMA, a wireless sub retinal photovoltaic implant designed to restore functional central vision in people living with advanced dry age related macular degeneration. In plain English, the technology acts as a bridge between light and neural signal, turning projected images into electrical stimulation the brain can interpret. When a company names itself Science, it probably helps if the science actually shows up.

This oversubscribed Series C round pulls in $230M from investors who have already been riding shotgun on the journey. Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT, and Quiet Capital doubled down on the thesis. When existing investors keep writing checks, it usually means the conversation inside the boardroom sounds less like hype and more like data.

The capital pushes total funding to roughly $490M and will move PRIMA toward commercialization while expanding clinical trials and scaling the infrastructure behind it. Manufacturing, research, operations. All the unsexy machinery required to turn a breakthrough into a real product doctors can deploy and patients can rely on.

Inside the lab, Chief Scientific Officer Alan Mardinly and the research teams are advancing the broader neural engineering stack that sits behind the implant. The company’s Science Foundry program also opens pieces of that infrastructure to other builders chasing breakthroughs in brain computer interfaces. Not just building technology but building the tools others need to build their own.

That combination is where the strategy starts to get interesting. A product that tackles blindness. A platform that accelerates the entire BCI ecosystem. And a company headquartered in Alameda with growing operations stretching to Research Triangle Park and Paris.

There is a particular rhythm to deep tech when it works. Years of quiet work. Small signals turning into clinical data. Clinical data turning into capital. Capital turning into scale. Somewhere in that cycle, something that once sounded impossible starts looking suspiciously inevitable.